Literature DB >> 12543812

Mechanisms by which tumor cells and monocytes expressing the angiogenic factor thymidine phosphorylase mediate human endothelial cell migration.

Kylie A Hotchkiss1, Anthony W Ashton, Robert S Klein, Michelle L Lenzi, Geng Hui Zhu, Edward L Schwartz.   

Abstract

The angiogenic factor thymidine phosphorylase (TP) is highly expressed in many human solid tumors, and the level of its expression is associated with tumor neovascularization, invasiveness, and metastasis and with shorter patient survival time. TP promotes endothelial cell (EC) migration in vitro and angiogenesis in vivo, and these have been linked to its enzymatic activity. The mechanism by which TP stimulates EC migration was investigated using human umbilical vein ECs (HUVECs). TP induced concentration-dependent HUVEC migration, which required a TP gradient and thymidine and which was abrogated by the TP inhibitor CIMU (5-chloro-6(1-imidazolylmethyl)uracil). The chemotactic actions of TP plus thymidine were duplicated by the TP metabolite, 2-deoxyribose-1-phosphate (dR-1-P), and 10-fold more potently by its subsequent metabolite, 2-deoxyribose (2dR). Migration induced by dR-1-P, but not 2dR, was blocked by an alkaline phosphatase inhibitor, suggesting that the actions of dR-1-P first required its conversion to 2dR. In the migration assay, [5'-3H]dThd was metabolized to dR-1-P (96%) and 2dR (3.8%), and a gradient of both metabolites was maintained between the lower and upper chambers over the entire 5-h assay. TP expression in human solid tumors occurs in both tumor epithelial cells and in tumor-associated macrophages. The migration assay was adapted to use TP-transfected carcinoma cells to stimulate HUVEC migration, and they were found to induce more migration than did control vector-transfected cells. Human monocyte cells U937 and THP1, which constitutively expressed high levels of TP, also strongly induced HUVEC migration in the coculture assay. CIMU inhibited tumor-cell and monocyte-induced migration. In contrast, a neutralizing antibody to TP had no effect on cell-stimulated HUVEC migration, even though it completely blocked the migration mediated by purified TP. Thus, the intracellular actions of TP were sufficient to stimulate HUVEC chemotaxis. In contrast to purified TP, when incubated with [5'-3H]-thymidine, cells expressing TP released up to 20-fold more 2dR into the medium than dR-1-P. These studies demonstrate that TP-expressing cells mediate EC migration via the intracellular metabolism of thymidine and subsequent extracellular release of 2dR, which forms a chemotactic gradient.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12543812

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

1.  Transfection of thymidine phosphorylase cDNA to human hepatocellular carcinoma cells enhances sensitivity to fluoropyrimidine but augments endothelial cell migration.

Authors:  Jian Zhou; Yong-Sheng Xiao; Zhao-You Tang; Jia Fan; Zhi-Quan Wu; Yan Zhao; Qiong Xue; Zao-Zhuo Shen; Yin-Kun Liu; Sheng-Long Ye
Journal:  J Cancer Res Clin Oncol       Date:  2005-04-30       Impact factor: 4.553

2.  Diffusion phenomena of cells and biomolecules in microfluidic devices.

Authors:  Ece Yildiz-Ozturk; Ozlem Yesil-Celiktas
Journal:  Biomicrofluidics       Date:  2015-07-01       Impact factor: 2.800

3.  Effects of thymidine phosphorylase on tumor aggressiveness and 5-fluorouracil sensitivity in cholangiocarcinoma.

Authors:  Jongkonnee Thanasai; Temduang Limpaiboon; Patcharee Jearanaikoon; Banchob Sripa; Chawalit Pairojkul; Srisurang Tantimavanich; Masanao Miwa
Journal:  World J Gastroenterol       Date:  2010-04-07       Impact factor: 5.742

Review 4.  Role of tumor-associated macrophages in the progression of hepatocellular carcinoma.

Authors:  Ken Shirabe; Yohei Mano; Jun Muto; Rumi Matono; Takashi Motomura; Takeo Toshima; Kazuki Takeishi; Hidekaki Uchiyama; Tomoharu Yoshizumi; Akinobu Taketomi; Masaru Morita; Shunichi Tsujitani; Yoshihisa Sakaguchi; Yoshihiko Maehara
Journal:  Surg Today       Date:  2011-11-25       Impact factor: 2.549

5.  Synthesis and in vitro evaluation of 5-fluoro-6-[(2-iminopyrrolidin-1-YL)methyl]uracil, TPI(F): an inhibitor of human thymidine phosphorylase (TP).

Authors:  John R Grierson; J Scott Brockenbrough; Janet S Rasey; Linda Wiens; Hubert Vesselle
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2010-01       Impact factor: 1.381

Review 6.  Regulation of epithelial-mesenchymal transition by tumor-associated macrophages in cancer.

Authors:  Jia Zhang; Hongmei Yao; Ge Song; Xia Liao; Yao Xian; Weimin Li
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

7.  Thymidine phosphorylase exerts complex effects on bone resorption and formation in myeloma.

Authors:  Huan Liu; Zhiqiang Liu; Juan Du; Jin He; Pei Lin; Behrang Amini; Michael W Starbuck; Nora Novane; Jatin J Shah; Richard E Davis; Jian Hou; Robert F Gagel; Jing Yang
Journal:  Sci Transl Med       Date:  2016-08-24       Impact factor: 17.956

8.  Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo.

Authors:  Tashanna Myers; Shylet Chengedza; Stan Lightfoot; Yanfang Pan; Daynelle Dedmond; Lauren Cole; Yuhong Tang; Doris M Benbrook
Journal:  Invest New Drugs       Date:  2008-09-18       Impact factor: 3.850

9.  Thymidine kinase 1 and thymidine phosphorylase expression in non-small-cell lung carcinoma in relation to angiogenesis and proliferation.

Authors:  J Scott Brockenbrough; Janice K Morihara; Stephen E Hawes; Joshua E Stern; Janet S Rasey; Linda W Wiens; Qinghua Feng; Hubert Vesselle
Journal:  J Histochem Cytochem       Date:  2009-08-03       Impact factor: 2.479

10.  Antiangiogenic and antitumor activity of 6-(2-aminoethyl)amino-5-chlorouracil, a novel small-molecule inhibitor of thymidine phosphorylase, in combination with the vascular endothelial growth factor-trap.

Authors:  Haiyan Lu; Robert S Klein; Edward L Schwartz
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.